Trials / Completed
CompletedNCT00109252
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raptiva (efalizumab) |
Timeline
- Start date
- 2002-01-01
- Completion
- 2003-04-01
- First posted
- 2005-04-26
- Last updated
- 2013-06-21
Source: ClinicalTrials.gov record NCT00109252. Inclusion in this directory is not an endorsement.